Silence Therapeutics Says European Patent Office Upholds Validity of Amended Patent
October 22, 2009
Silence Therapeutics Says European Patent Office Upholds Validity of Amended Patent
According to Silence, the patent's amended claims "no longer cover other chemical modifications and molecular designs not used by Silence and which therefore do not have an impact on Silence’s core business."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Silence Responds to Alnylam European Patent Claims
March 15, 2012 / Gene Silencing News - EPO Upholds Claims in Silence Cancer Drug Patent
December 8, 2011 / Gene Silencing News - Novartis, Alcon Join Alnylam in Opposing Silence Patent in Europe
July 28, 2011 / Gene Silencing News - Alnylam Files Opposition Against Silence Patent in Europe
November 18, 2010 / Gene Silencing News - Silence Receives European Patent on RNAi Design Rules
October 21, 2010 / Gene Silencing News